FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I–III

BACKGROUND: Immunotherapies may prolong the survival of patients with small-cell lung cancer (SCLC) to some extent. The role of forkhead box protein P3 (FOXP3) in tumor microenvironment (TME) remains controversial. We aimed to examine FOXP3-related expression characteristics and prognostic values an...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Main Authors: Jiang, Minlin, Wu, Chunyan, Zhang, Liping, Sun, Chenglong, Wang, Hao, Xu, Yi, Sun, Hui, Zhu, Jun, Zhao, Wencheng, Fang, Qiyu, Yu, Jia, Chen, Peixin, Wu, Shengyu, Zheng, Zixuan, He, Yayi, Zhou, Caicun
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2021
Assuntos:
Immunotherapy Biomarkers
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8137193/
https://ncbi.nlm.nih.gov/pubmed/34006632
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2021-002339
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares